최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of clinical laboratory science : KJCLS = 대한임상검사과학회지, v.47 no.3, 2015년, pp.105 - 111
정혜선 (가톨릭대학교 성빈센트병원 진단검사의학과) , 강윤정 (단국대학교 일반대학원 보건학과)
In late December 2013, the Ebola virus emerged from West Africa. The outbreak started in Guinea and rapidly spread to Liberia and Sierra Leone. Initially, the virus is spread to the human population after contact with infected wildlife and then spread person-to-person through direct contact with bod...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
에볼라 바이러스의 전염 경로는? | 체액 손실로 인한 저혈압으로 치사율은 25∼90%에 이른다(Organization, 2014). 에볼라 바이러스는 땀과 침, 혈액, 림프액, 분비물, 정액, 모유 등 체액의 직접접촉을 통해 전염된다(Bausch 등, 2007). 일반적으로 공기전염으로는 확산되지는 않는다(Francesconi 등, 2003). | |
에볼라 바이러스 감염 증상은? | 감염자의 분비물을 통한 바이러스 감염의 확산으로 의료 관련 종사자들의 2차 감염이 미국과 스페인에서 보고되었다(Organization, 2015). 심각한 출혈열(severe hemorrhagic fever)을 일으키는 바이러스로 증상은 일반적으로 발열, 목의 통증, 근육통, 두통, 간과 신장의 기능저하와 함께 구토, 설사, 발진 등을 나타나며, 장기 내부와 외부에서 출혈 증세를 나타내기도 한다. 체액 손실로 인한 저혈압으로 치사율은 25∼90%에 이른다(Organization, 2014). | |
에볼라 바이러스의 종류는? | 에볼라 바이러스는 유전체 염기서열의 계통분류학적 유사성에 따라 5가지 아형으로 분류되고 있다. 자이르형 에볼라(Zaire ebolavirus, EBOV-Z), 수단형 에볼라(Sudan ebolavirus, EBOV-S), 레스턴형 에볼라(Reston ebolavirus, EBOV-R), 코트디브아르형 에볼라(Tai Forest ebolavirus, 이전 Côte d’Ivoire ebolavirus, EBOV-TF) 그리고 분디부교형 에볼라(Bundibugyo ebolavirus, EBOV-B)가 있다(Feldmann & Geisbert, 2011). 레스턴형은 1989년 미국 버지니아의 레스턴(Reston)에 수입된 필리핀 원숭이(Macaca fascicularis)의 검역과정에서 직원이 감염되었다(Jahrling 등, 1990). |
Barrette RW, SA Metwally, JM Rowland, L Xu, SR Zaki, ST Nichol, P, et al. Discovery of swine as a host for the Reston ebolavirus. Science. 2009, 325(5937): 204-206.
Bausch DG, JS Towner, SF Dowell, F Kaducu, M. Lukwiya, A Sanchez, et al.. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. Journal of Infectious Diseases. 2007, 196(Supplement 2): S142-S147.
Bwaka MA, M.J Bonnet, P Calain, R Colebunders, A De Roo, Y Guimard, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. Journal of Infectious Diseases. 1999, 179(Supplement 1): S1-S7.
Dixon MG, IJ Schafer. Ebola viral disease outbreak-West Africa, 2014. MMWR Morb Mortal Wkly Rep 2014, 63(25):548-551.
Feldmann H, TW Geisbert. Ebola haemorrhagic fever. The Lancet. 2001, 377(9768): 849-862.
Feldmann H, HD Klenk. Marburg and Ebola viruses. Advances in Virus Research. 1996, 47: 1-52.
Formenty P, C Hatz, B Le Guenno, A Stoll, P Rogenmoser, A Widmer. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. Journal of Infectious Diseases. 1999, 179(Supplement 1): S48-S53.
Francesconi P, Z Yoti, S Declich, PA Onek, M Fabiani, J Olango, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerging Infectious Diseases. 2003, 9(11):1430.
Geisbert TW, ACH Lee, M. Robbins, JB Geisbert, AN Honko, V Sood, et al.. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet. 2010, 375(9729): 1896-1905.
Grolla A, A Lucht, D Dick, JE Stron, H Feldmann. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot. 2005, 98(3): 205.
J Alimonti, A Leung, S Jones, J Gren, X Qiu, L Fernando, et al. Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Scientific Reports 4. 2014, doi:10.1038/srep05824.
Jahrling PB, TW Geisbert, ED Johnson, CJ Peters, D Dalgard, W. Hall. Preliminary report: isolation of Ebola virus from monkeys imported to USA. The Lancet. 1990, 335(8688): 502-505.
Kanapathipillai R, AM Henao Restrepo, P Fast, D Wood, C Dye, M.P Kieny, et al. Ebola vaccine-an urgent international priority. New England Journal of Medicine. 2014, 371(24): 2249-2251.
Kilgore PE, JD Grabenstein, AM Salim, M. Rybak. Treatment of ebola virus disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015, 35(1): 43-53.
Kortepeter MG, DG Bausch, M Bray. "Basic clinical and laboratory features of filoviral hemorrhagic fever." Journal of Infectious Diseases. 2011, 204(suppl 3): S810-S816.
Leroy EM, S Baize, CY Lu, J McCormick, A Georges, M Georges-Courbot, et al. Diagnosis of Ebola haemorrhagic fever by RTPCR in an epidemic setting. Journal of Medical Virology. 2000, 60(4): 463-467.
Martin P. KB Laupland, EH Frost, L. Valiquette. Laboratory diagnosis of Ebola virus disease. Intensive Care Medicine. 2015, 1-4.
Oestereich L, A Ludtke, S Wurr, T Rieger, C Munoz-Fontela, S. Gunther. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research. 2014, 105: 17-21.
World Health Organization. Viral haemorrhagic fever in imported monkeys. Wkly Epidemiol Rec.1992, 67(142): 20849-26003.
World Health Organization. Ebola virus disease. Fact sheet No. 103, updated September 2014.
World Health Organization. Ebola situation report. WHO Geneva, MAY. 2015.
Qiu X, G Wong, J Audet, A Bello, L Fernando, JB Alimonti, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014, doi:10.1038/nature13777.
Saez AM, S Weiss, K Nowak, V Lapeyre, F Zimmermann, A Dux, et al.. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Molecular Medicine. 2015, 7(1): 17-23.
Schieffelin JS, JG Shaffer, A Goba, M Gbakie, SK Gire, A Colubri, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. New England Journal of Medicine. 2014, 371(22):2092-2100.
Smither SJ, LS Eastaugh, JA Steward, M Nelson, RP Lenk, M. S. Lever. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Research. 2014, 104: 153-155.
Towner JS, TK Sealy, ML Khristova, CG. Albarino, S Conlan, SA Reeder, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens. 2008, 4(11): e1000212.
Volchkov VE, H Feldmann, VA Volchkova, HD Klenk. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proceedings of the National Academy of Sciences. 1998, 95(10): 5762-5767.
Volchkov VE, VA Volchkova, E Muhlberger, LV Kolesnikova, M Weik, O Dolnik et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science. 2001, 291(5510): 1965-1969.
West TE, A von Saint Andre-von Arnim. Clinical Presentation and Management of Severe Ebola Virus Disease. Annals of the American Thoracic Society. 2014, 11(9): 1341-1350.
Zaki SR, WJ Shieh, PW Greer, CS Goldsmith, T Ferebee, J Katshitshi, et al.. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Journal of Infectious Diseases. 1999, 179(Supplement 1): S36-S47.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.